Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 2
1996 9
1997 8
1998 7
1999 8
2000 9
2001 8
2002 7
2003 4
2004 7
2005 12
2006 12
2007 13
2008 16
2009 8
2010 5
2011 3
2012 3
2013 4
2014 1
2015 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

137 results

Results by year

Filters applied: . Clear all
Page 1
Real-world impact of neurocognitive deficits in acute and early HIV infection.
Doyle KL, Morgan EE, Morris S, Smith DM, Little S, Iudicello JE, Blackstone K, Moore DJ, Grant I, Letendre SL, Woods SP; Translational Methamphetamine AIDS Research Center (TMARC) Group. Doyle KL, et al. J Neurovirol. 2013 Dec;19(6):565-73. doi: 10.1007/s13365-013-0218-2. Epub 2013 Nov 26. J Neurovirol. 2013. PMID: 24277439 Free PMC article.
Mitochondrial DNA variation and changes in adiponectin and endothelial function in HIV-infected adults after antiretroviral therapy initiation.
Hulgan T, Stein JH, Cotter BR, Murdock DG, Ritchie MD, Dube MP, Gerschenson M, Haas DW, Torriani FJ; Aids Clinical Trials Group A5152s And Dacs 252 Study Teams. Hulgan T, et al. AIDS Res Hum Retroviruses. 2013 Oct;29(10):1293-9. doi: 10.1089/aid.2013.0079. Epub 2013 Aug 14. AIDS Res Hum Retroviruses. 2013. PMID: 23944767 Free PMC article. Clinical Trial.
Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection.
Haubrich RH, Riddler SA, Ribaudo H, Direnzo G, Klingman KL, Garren KW, Butcher DL, Rooney JF, Havlir DV, Mellors JW; AIDS Clinical Trials Group (ACTG) A5160 and A5142 Study Teams. Haubrich RH, et al. AIDS. 2011 Nov 28;25(18):2269-78. doi: 10.1097/QAD.0b013e32834d0c20. AIDS. 2011. PMID: 21941167 Free PMC article. Clinical Trial.
137 results